Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older

Abstract

Patients aged 80 years and older make up a fifth of patients with CLL but are underrepresented in clinical trials. We analyzed the outcomes of these patients treated with targeted agents in the front-line setting in six trials of the German CLL Study Group. Targeted agents included venetoclax, ibrutinib, and idelalisib, mainly used in combination with anti-CD20 antibodies. Among 716 patients, 33 matched the selection criteria (5%). Of those, the majority had relevant comorbidity, organ dysfunctions, and/or high-/very high-risk disease. The overall response rate was 73%. The median progression-free survival was 49.2 months compared with those not reached in younger patients. There were 11 documented deaths of which two were deemed related to therapy. Additional results including 40 patients treated with BTK-inhibitors from the GCLLSG registry suggest that treatment with targeted agents is feasible and effective. Dedicated studies are warranted for this particular subgroup of patients.

Keywords:

• CLL
• elderly
• geriatric oncology
• targeted treatment

Acknowledgments

We thank the patients and their families, as well as the investigators, nurses and site staff for their trust and support in our studies.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

OAS is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Projektnummer 467697427.